{"id":54517,"date":"2024-04-17T18:00:00","date_gmt":"2024-04-17T16:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/"},"modified":"2024-07-23T11:57:00","modified_gmt":"2024-07-23T09:57:00","slug":"ipsen-publie-son-document-denregistrement-universel-2023","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/","title":{"rendered":"Ipsen publie son Document d\u2019enregistrement universel 2023"},"content":{"rendered":"<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:21.85%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:28.15%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"><strong>Ipsen publie son<\/strong><br \/><strong>Document d\u2019enregistrement universel 2023<\/strong><\/p>\n<p align=\"justify\"><strong>PARIS, FRANCE, 17 avril 2024 <\/strong>&#8211; Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9 annonce que son Document d\u2019enregistrement universel 2023 a \u00e9t\u00e9 d\u00e9pos\u00e9 le 17 avril 2024 aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers (AMF) et enregistr\u00e9 sous le num\u00e9ro D.24-0288.<\/p>\n<p align=\"justify\">Ce document peut \u00eatre consult\u00e9 sur le site internet de la soci\u00e9t\u00e9 \u00e0 l\u2019adresse <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a0E3kEO0-Hpp60ORG7idKRakXwrAbK0YHp5PmvhGimOoMME1Io5BAOkCur3oI09RhG3IoaalC8Nsm9ospWIrFw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.ipsen.com\">www.ipsen.com<\/a> et sur le site de l\u2019AMF <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a0E3kEO0-Hpp60ORG7idKT7yhTOS6CAEtAV6jNTDhMnV5cXeBmGo_SG5X_8mYEu712wBX1hiyAJRYVRBKGwHlj3mmgcb3t55Del_zSuLte8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.amf-france.org\">www.amf-france.org<\/a>. Il sera \u00e9galement tenu \u00e0 disposition au si\u00e8ge social de la Soci\u00e9t\u00e9 \u2013 65 quai Georges Gorse, 92100 Boulogne-Billancourt \u2013 France.<\/p>\n<p align=\"justify\">Les documents suivants sont notamment int\u00e9gr\u00e9s dans le Document d\u2019enregistrement universel 2023\u00a0:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Le Rapport Financier Annuel ;<\/li>\n<li style=\"text-align:justify\">Le Rapport du Conseil d&#8217;administration sur le gouvernement d&#8217;entreprise.<\/li>\n<\/ul>\n<p align=\"justify\"><strong>A propos d\u2019Ipsen<\/strong><\/p>\n<p align=\"justify\">Nous sommes un groupe biopharmaceutique mondial focalis\u00e9 sur la mise au point de m\u00e9dicaments innovants pour les patients dans trois domaines th\u00e9rapeutiques : l&#8217;Oncologie, les Maladies Rares et les Neurosciences.<\/p>\n<p align=\"justify\">Notre portefeuille de produits en R&amp;D s&#8217;appuie sur l&#8217;innovation externe et sur pr\u00e8s de 100 ans d&#8217;exp\u00e9rience de d\u00e9veloppement au sein de hubs mondiaux aux \u00c9tats-Unis, en France et au Royaume-Uni. Nos \u00e9quipes, pr\u00e9sentes dans plus de 40 pays, et nos partenariats \u00e0 travers le monde nous permettent de proposer nos m\u00e9dicaments aux patients dans plus de 80 pays.<\/p>\n<p align=\"justify\">Ipsen est cot\u00e9 \u00e0 Paris (Euronext : IPN) et aux Etats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Pour plus d&#8217;informations, consultez ipsen.com<\/p>\n<p align=\"justify\"><strong>Contacts Ipsen<\/strong><\/p>\n<p align=\"justify\"><strong>Investisseurs<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\"><strong>Craig Marks <\/strong>| + 44 (0) 7584 349 193<\/li>\n<li style=\"margin-top:12pt;margin-bottom:6pt;text-align:justify\"><strong>Nicolas Bogler <\/strong>| + 33 (6) 52 19 98 92<\/li>\n<\/ul>\n<p align=\"justify\"><strong>M\u00e9dias<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\"><strong>Amy Wolf <\/strong>| + 41 (0) 79 576 07 23<\/li>\n<li style=\"text-align:justify\"><strong>Iona Piscociu<\/strong> | + 33 (0) 6 69 09 12 96<\/li>\n<\/ul>\n<p align=\"justify\"><strong>Avertissements et\/ou d\u00e9clarations prospectives<\/strong><\/p>\n<p>Les d\u00e9clarations prospectives et les objectifs contenus dans ce communiqu\u00e9 sont bas\u00e9s sur la strat\u00e9gie et les hypoth\u00e8ses actuelles de la Direction d\u2019Ipsen. Ces d\u00e9clarations et objectifs d\u00e9pendent de risques et d\u2019incertitudes connus ou non qui peuvent entra\u00eener une divergence significative entre les r\u00e9sultats, performances ou \u00e9v\u00e9nements effectifs et ceux envisag\u00e9s dans ce communiqu\u00e9 De tels risques et impr\u00e9vus pourraient affecter la capacit\u00e9 d\u2019Ipsen \u00e0 atteindre ses objectifs financiers, lesquels reposent sur des hypoth\u00e8ses raisonnables quant aux conditions macro\u00e9conomiques \u00e0 venir formul\u00e9es d\u2019apr\u00e8s les informations disponibles \u00e0 ce jour. L&#8217;utilisation des termes \u00ab\u00a0croit\u00a0\u00bb, \u00ab\u00a0envisage\u00a0\u00bb et \u00ab\u00a0pr\u00e9voit\u00a0\u00bb ou d&#8217;expressions similaires a pour but d&#8217;identifier des \u00e9nonc\u00e9s prospectifs, notamment les attentes d\u2019Ipsen quant \u00e0 des \u00e9v\u00e9nements futurs tels que les soumissions et d\u00e9cisions r\u00e9glementaires. De plus, les objectifs mentionn\u00e9s dans ce document sont \u00e9tablis sans tenir compte d\u2019\u00e9ventuelles op\u00e9rations futures de croissance externe qui pourraient venir modifier tous ces param\u00e8tres. Ces pr\u00e9visions sont notamment fond\u00e9es sur des donn\u00e9es et hypoth\u00e8ses consid\u00e9r\u00e9es comme raisonnables par Ipsen, et d\u00e9pendent de circonstances ou de faits susceptibles de se produire \u00e0 l\u2019avenir et dont certains \u00e9chappent au contr\u00f4le du Groupe, et non pas exclusivement de donn\u00e9es historiques. Les r\u00e9sultats r\u00e9els pourraient s\u2019av\u00e9rer substantiellement diff\u00e9rents de ces objectifs compte tenu de la mat\u00e9rialisation de certains risques ou incertitudes, et notamment qu\u2019un nouveau m\u00e9dicament peut para\u00eetre prometteur au cours d\u2019une phase pr\u00e9paratoire de d\u00e9veloppement ou apr\u00e8s des essais cliniques, mais n\u2019\u00eatre jamais commercialis\u00e9 ou ne pas atteindre ses objectifs commerciaux, notamment pour des raisons r\u00e9glementaires ou concurrentielles. Ipsen doit ou peut avoir \u00e0 faire face \u00e0 la concurrence de produits g\u00e9n\u00e9riques, qui pourrait se traduire par des pertes de parts de march\u00e9. En outre, le processus de recherche et d\u00e9veloppement comprend plusieurs \u00e9tapes et, lors de chaque \u00e9tape, le risque est important qu\u2019Ipsen ne parvienne pas \u00e0 atteindre ses objectifs et qu\u2019il soit conduit \u00e0 renoncer \u00e0 poursuivre ses efforts sur un m\u00e9dicament dans lequel il a investi des sommes significatives. Aussi, Ipsen ne peut \u00eatre certain que des r\u00e9sultats favorables obtenus lors des essais pr\u00e9cliniques seront confirm\u00e9s ult\u00e9rieurement lors des essais cliniques ou que les r\u00e9sultats des essais cliniques seront suffisants pour d\u00e9montrer le caract\u00e8re s\u00fbr et efficace du m\u00e9dicament concern\u00e9. Il ne saurait \u00eatre garanti qu\u2019un m\u00e9dicament recevra les approbations r\u00e9glementaires n\u00e9cessaires ou qu\u2019il atteindra ses objectifs commerciaux. Les r\u00e9sultats r\u00e9els pourraient \u00eatre sensiblement diff\u00e9rents de ceux annonc\u00e9s dans les d\u00e9clarations pr\u00e9visionnelles si les hypoth\u00e8ses sous-jacentes s&#8217;av\u00e8rent inexactes ou si certains risques ou incertitudes se mat\u00e9rialisent. Les autres risques et incertitudes comprennent, sans toutefois s&#8217;y limiter, la situation g\u00e9n\u00e9rale du secteur et la concurrence\u00a0; les facteurs \u00e9conomiques g\u00e9n\u00e9raux, y compris les fluctuations des taux d&#8217;int\u00e9r\u00eat et des taux de change\u00a0; l&#8217;incidence de la r\u00e9glementation de l&#8217;industrie pharmaceutique et de la l\u00e9gislation en mati\u00e8re de sant\u00e9\u00a0; les tendances mondiales vers une plus grande ma\u00eetrise des co\u00fbts de sant\u00e9\u00a0; les avanc\u00e9es technologiques, les nouveaux m\u00e9dicaments et les brevets obtenus par la concurrence\u00a0; les probl\u00e8mes inh\u00e9rents au d\u00e9veloppement de nouveaux m\u00e9dicaments, notamment l&#8217;obtention d&#8217;une homologation\u00a0; la capacit\u00e9 d\u2019Ipsen \u00e0 pr\u00e9voir avec pr\u00e9cision les futures conditions du march\u00e9\u00a0; les difficult\u00e9s ou d\u00e9lais de production\u00a0; l&#8217;instabilit\u00e9 financi\u00e8re de l&#8217;\u00e9conomie internationale et le risque souverain\u00a0; la d\u00e9pendance \u00e0 l&#8217;\u00e9gard de l&#8217;efficacit\u00e9 des brevets d\u2019Ipsen et d\u2019autres protections concernant les m\u00e9dicaments novateurs\u00a0; et le risque de litiges, notamment des litiges en mati\u00e8re de brevets ou des recours r\u00e9glementaires. Ipsen d\u00e9pend \u00e9galement de tierces parties pour le d\u00e9veloppement et la commercialisation de ses m\u00e9dicaments, ce qui peut donner lieu \u00e0 des redevances substantielles\u00a0; en outre ces partenaires pourraient agir de mani\u00e8re \u00e0 nuire aux activit\u00e9s d\u2019Ipsen ainsi qu\u2019\u00e0 ses r\u00e9sultats financiers. Ipsen ne peut \u00eatre certain que ses partenaires tiendront leurs engagements. \u00c0 ce titre, le Groupe pourrait ne pas \u00eatre en mesure de b\u00e9n\u00e9ficier de ces accords. Une d\u00e9faillance d\u2019un de ses partenaires pourrait engendrer une baisse impr\u00e9vue de revenus pour Ipsen. De telles situations pourraient avoir un impact n\u00e9gatif sur l\u2019activit\u00e9 d\u2019Ipsen, sa situation financi\u00e8re ou ses r\u00e9sultats. Sous r\u00e9serve des dispositions l\u00e9gales en vigueur, Ipsen ne prend aucun engagement de mettre \u00e0 jour ou de r\u00e9viser les \u00e9nonc\u00e9s prospectifs ou objectifs vis\u00e9s dans le pr\u00e9sent communiqu\u00e9 afin de refl\u00e9ter des changements qui viendraient affecter les \u00e9v\u00e9nements, situations, hypoth\u00e8ses ou circonstances sur lesquels ces \u00e9nonc\u00e9s se fondent. L\u2019activit\u00e9 d\u2019Ipsen est soumise \u00e0 des facteurs de risques qui sont d\u00e9crits dans ses documents d\u2019information enregistr\u00e9s aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers. Les risques et incertitudes pr\u00e9sent\u00e9s ne sont pas les seuls auxquels le Groupe doit faire face et le lecteur est invit\u00e9 \u00e0 prendre connaissance de la derni\u00e8re \u00e9dition du Document d\u2019enregistrement universel d\u2019Ipsen, disponible sur <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=drKzI9wsHyihV64uEBfOpJAHKIZZHIDlbOu7YWcQPwtSFuTZuLqfHuzBoVsO3eUgIpGs8eRKKQIKH9NxUQaYDnJRvRo6CXbgobLMQmxEnS0HcdP5hJk9Xyias_ku7W8Thbo_jsQ9PyfGufeaJPJBsk09dPxcxdOhPewbXX4GTT--d-momKU8C7oXsRkBa5mtFX-o6WTEVerplXG4yPpcQs9dcjKLbmYOUK8kLH3AvJg=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ipsen.com\">ipsen.com<\/a>.<\/p>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=lJVbqggVgG60QN5ed8U2kME3Z1Lew_GgFZGhA0lyZIBP3aPnpPRcc7apjG1JwJyeH0cTWiV1cwN6seaFgW3EXGuVNrHofmJHTGAOUjo0oxYMN9IpBAujM0MWKaAKeef6dW_6iX1CxAuNDYBeJGy33fPmaY0G9xBXj67uair_zFgD2RriYRcp9ZjX259RpVVRfpbCcOVRDMb_iEDF8e4epA==\" title=\"Ipsen SA_D&#233;p&#244;t_DEU_2023_AMF\" rel=\"nofollow noopener\">Ipsen SA_D&#233;p&#244;t_DEU_2023_AMF<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233],"tags":[],"class_list":["post-54517","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen publie son Document d\u2019enregistrement universel 2023<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen publie son Document d\u2019enregistrement universel 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-23T09:57:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen publie son Document d\u2019enregistrement universel 2023\",\"datePublished\":\"2024-04-17T16:00:00+00:00\",\"dateModified\":\"2024-07-23T09:57:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\"},\"wordCount\":1207,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\",\"name\":\"Ipsen publie son Document d\u2019enregistrement universel 2023\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2024-04-17T16:00:00+00:00\",\"dateModified\":\"2024-07-23T09:57:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen publie son Document d\u2019enregistrement universel 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen publie son Document d\u2019enregistrement universel 2023","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen publie son Document d\u2019enregistrement universel 2023","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/","og_site_name":"Global","article_modified_time":"2024-07-23T09:57:00+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen publie son Document d\u2019enregistrement universel 2023","datePublished":"2024-04-17T16:00:00+00:00","dateModified":"2024-07-23T09:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/"},"wordCount":1207,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","articleSection":["Communiqu\u00e9 de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/","name":"Ipsen publie son Document d\u2019enregistrement universel 2023","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","datePublished":"2024-04-17T16:00:00+00:00","dateModified":"2024-07-23T09:57:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmE5OWZmZjAtMDE1ZS00ZTVmLTkyNjMtMzI4YTQ4ODA0N2E5LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-publie-son-document-denregistrement-universel-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Ipsen publie son Document d\u2019enregistrement universel 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/54517"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/54517\/revisions"}],"predecessor-version":[{"id":62367,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/54517\/revisions\/62367"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=54517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=54517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=54517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}